stars 1 stars 2 stars 3

HypoPet is a Swiss biotech company engaged in the research, development, manufacture and licensing of therapeutic vaccines for major unmet needs in companion animal medicine; allergy, inflammation, pain, cardiovascular and metabolic disease and cancer. HypoPet has developed and patented a recombinant virus-like particle vaccine platform, which can be used to induce long-lived antibodies that specifically target key molecules that drive chronic diseases. With our technology we aim to leverage the profound success achieved with human monoclonal antibodies into cost-effective treatments for pets.

HypoPet AG Questions

The HypoPet AG annual revenue was $6 million in 2026.

HypoPet AG is based in Schlieren, Zurich.

The NAICS codes for HypoPet AG are [32541, 325, 3254, 32].

The SIC codes for HypoPet AG are [28, 283].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users